Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJoseph Gligorov, Luis Matamala, Beyhan Ataseven et al.|European Journal of Cancer|2017Cited by 47
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019Joanna Gotfrit, Michael M. Vickers, Dominick Bossé et al.|Current Oncology|2021Cited by 6
Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A multicenter analysis from the CHORD consortium.Sakshi Mehta, Brandon M. Meyers, M-J.D.V.B.A.D.C. Cardoso et al.|Journal of Clinical Oncology|2020Cited by 0